NCT06753942View on ClinicalTrials.gov

ANTI-SARS-CoV-2 SEROCONVERSIO IN IMMUNE-MEDIATED KIDNEY DISEASES

CompletedOBSERVATIONAL
Enrollment

120

Participants

Timeline

Start Date

September 9, 2022

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions
Immune-mediated DiseasesGlomerulonephritis
Trial Locations (1)

40138

IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna

All Listed Sponsors
lead

IRCCS Azienda Ospedaliero-Universitaria di Bologna

OTHER